PA8542401A1 - Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad - Google Patents

Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad

Info

Publication number: PA8542401A1
Authority: PA; Panama
Prior art keywords: replaced; optionally replaced; fenpropilciclopentilo; fsad; nep inhibitors
Prior art date: 2001-03-28

Application number

PA20028542401A

Other languages

English (en)

Spanish (es)

Inventor

Donald Stuart Middleton

Andrew Simon Cook

David Cameron Pryde

Alan Stobie

Stephen Challenger

Adam Thomas Gillmore

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-28

Filing date

2002-03-27

Publication date

2002-10-28

2001-03-28 Priority claimed from GB0107750A external-priority patent/GB0107750D0/en

2001-05-30 Priority claimed from GB0113112A external-priority patent/GB0113112D0/en

2001-08-17 Priority claimed from GB0120152A external-priority patent/GB0120152D0/en

2002-03-27 Application filed by Pfizer filed Critical Pfizer

2002-10-28 Publication of PA8542401A1 publication Critical patent/PA8542401A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gynecology & Obstetrics (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Dispersion Chemistry (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Quinoline Compounds (AREA)
Furan Compounds (AREA)
Pyrane Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

PA20028542401A 2001-03-28 2002-03-27 Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad PA8542401A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0107750A GB0107750D0 (en)	2001-03-28	2001-03-28	Novel pharmaceuticals
GB0113112A GB0113112D0 (en)	2001-05-30	2001-05-30	Novel pharmaceuticals
GB0120152A GB0120152D0 (en)	2001-08-17	2001-08-17	Novel pharmaceuticals

Publications (1)

Publication Number	Publication Date
PA8542401A1 true PA8542401A1 (es)	2002-10-28

Family

ID=27256128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PA20028542401A PA8542401A1 (es)	2001-03-28	2002-03-27	Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad

Country Status (34)

Country	Link
EP (1)	EP1373192A1 (pt)
JP (1)	JP4018545B2 (pt)
KR (1)	KR100564466B1 (pt)
CN (1)	CN1243723C (pt)
AP (1)	AP1689A (pt)
AR (1)	AR035795A1 (pt)
BG (1)	BG108130A (pt)
BR (1)	BR0208455A (pt)
CA (1)	CA2437113A1 (pt)
CZ (1)	CZ20032534A3 (pt)
DO (1)	DOP2002000364A (pt)
EA (1)	EA006154B1 (pt)
EE (1)	EE200300469A (pt)
GE (1)	GEP20063783B (pt)
HK (1)	HK1060724A1 (pt)
HR (1)	HRP20030751A2 (pt)
HU (1)	HUP0303624A3 (pt)
IL (1)	IL157009A0 (pt)
IS (1)	IS6877A (pt)
MA (1)	MA26996A1 (pt)
MX (1)	MXPA03006597A (pt)
MY (1)	MY134081A (pt)
NO (1)	NO20034299L (pt)
NZ (1)	NZ527012A (pt)
OA (1)	OA12553A (pt)
PA (1)	PA8542401A1 (pt)
PE (1)	PE20021014A1 (pt)
PL (1)	PL365101A1 (pt)
RS (1)	RS75303A (pt)
SK (1)	SK11822003A3 (pt)
TN (1)	TNSN02032A1 (pt)
TW (1)	TWI254038B (pt)
UY (1)	UY27227A1 (pt)
WO (1)	WO2002079143A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040014761A1 (en) *	1997-10-28	2004-01-22	Place Virgil A.	Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US7183410B2 (en)	2001-08-02	2007-02-27	Bidachem S.P.A.	Stable polymorph of flibanserin
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
WO2003039524A1 (en) *	2001-11-09	2003-05-15	Pharmacia Ab	Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction
GB0230036D0 (en) *	2002-12-23	2003-01-29	Pfizer Ltd	Novel pharmaceuticals
GB0230025D0 (en) *	2002-12-23	2003-01-29	Pfizer Ltd	Novel pharmaceuticals
PA8597401A1 (es) *	2003-03-14	2005-05-24	Pfizer	Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US7262184B2 (en)	2003-09-26	2007-08-28	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en)	2003-09-26	2008-11-18	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en)	2003-09-26	2008-09-23	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
AU2005239962B2 (en)	2004-05-11	2011-07-07	Eb Ip Lybrido B.V.	Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20060025420A1 (en) *	2004-07-30	2006-02-02	Boehringer Ingelheimn International GmbH	Pharmaceutical compositions for the treatment of female sexual disorders
WO2006027680A1 (en) *	2004-09-10	2006-03-16	Pfizer Limited	3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
EP1912650B8 (en)	2005-08-03	2017-10-18	Sprout Pharmaceuticals, Inc.	Use of flibanserin in the treatment of obesity
CA2626134C (en)	2005-10-29	2013-12-24	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) *	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
DE602007004615D1 (de)	2006-06-30	2010-03-18	Boehringer Ingelheim Pharma	Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
EA200900264A1 (ru)	2006-08-14	2009-08-28	Бёрингер Ингельхайм Интернациональ Гмбх	Композиции флибансерина и способ их приготовления
CN101505736A (zh)	2006-08-25	2009-08-12	贝林格尔.英格海姆国际有限公司	控制释放系统及其制造方法
US8198311B2 (en) *	2006-11-01	2012-06-12	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1925307A1 (en)	2006-11-03	2008-05-28	Emotional Brain B.V.	Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
CL2008002693A1 (es)	2007-09-12	2009-10-16	Boehringer Ingelheim Int	Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
EP3082428A4 (en)	2013-12-09	2017-08-02	Respira Therapeutics, Inc.	Pde5 inhibitor powder formulations and methods relating thereto
SI3303330T1 (sl)	2015-06-03	2019-08-30	Bristol-Myers Squibb Company	Agonisti 4-hidroksi-3-(heteroaril)piridin-2-on apj za uporabo pri zdravljenju kardiovaskularnih motenj
MX2019006938A (es)	2016-12-14	2019-09-06	Respira Therapeutics Inc	Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
CN107746400A (zh) *	2017-12-04	2018-03-02	武汉药明康德新药开发有限公司	苯并二氢吡喃‑6‑磺酰氯的制备方法
BR112020018094A2 (pt)	2018-03-08	2020-12-22	Incyte Corporation	Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
CN110483403A (zh) *	2019-09-02	2019-11-22	南通大学	一种5-溴-4-甲氧基-1h-吲唑的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH075530B2 (ja)	1989-11-21	1995-01-25	シェリング・コーポレーション	カルボキシアルキルカルボニルアミノ酸エンドペプチダーゼ阻害剤
GB9000725D0 (en)	1990-01-12	1990-03-14	Pfizer Ltd	Therapeutic agents
GB9004260D0 (en)	1990-02-26	1990-04-18	Pfizer Ltd	Therapeutic agents
US5208236A (en) *	1992-09-23	1993-05-04	Schering Corporation	N-(acylaminomethyl)glutaryl amino acids and use
IL139457A0 (en)	1999-11-08	2001-11-25	Pfizer	Compounds for the treatment of female sexual dysfunction
US20020052370A1 (en) *	2000-07-06	2002-05-02	Barber Christopher Gordon	Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

2002
- 2002-03-18 IL IL15700902A patent/IL157009A0/xx unknown
- 2002-03-18 CZ CZ20032534A patent/CZ20032534A3/cs unknown
- 2002-03-18 JP JP2002577770A patent/JP4018545B2/ja not_active Expired - Fee Related
- 2002-03-18 SK SK1182-2003A patent/SK11822003A3/sk unknown
- 2002-03-18 GE GE5313A patent/GEP20063783B/en unknown
- 2002-03-18 CA CA002437113A patent/CA2437113A1/en not_active Abandoned
- 2002-03-18 CN CNB028054091A patent/CN1243723C/zh not_active Expired - Fee Related
- 2002-03-18 EA EA200300777A patent/EA006154B1/ru unknown
- 2002-03-18 EP EP02707042A patent/EP1373192A1/en not_active Withdrawn
- 2002-03-18 WO PCT/IB2002/000807 patent/WO2002079143A1/en active IP Right Grant
- 2002-03-18 EE EEP200300469A patent/EE200300469A/xx unknown
- 2002-03-18 DO DO2002000364A patent/DOP2002000364A/es unknown
- 2002-03-18 KR KR1020037012690A patent/KR100564466B1/ko not_active IP Right Cessation
- 2002-03-18 BR BR0208455-4A patent/BR0208455A/pt not_active IP Right Cessation
- 2002-03-18 HU HU0303624A patent/HUP0303624A3/hu unknown
- 2002-03-18 OA OA1200300204A patent/OA12553A/en unknown
- 2002-03-18 RS YU75303A patent/RS75303A/sr unknown
- 2002-03-18 NZ NZ527012A patent/NZ527012A/en unknown
- 2002-03-18 MX MXPA03006597A patent/MXPA03006597A/es active IP Right Grant
- 2002-03-18 PL PL02365101A patent/PL365101A1/xx not_active Application Discontinuation
- 2002-03-22 TW TW091105650A patent/TWI254038B/zh not_active IP Right Cessation
- 2002-03-25 UY UY27227A patent/UY27227A1/es not_active Application Discontinuation
- 2002-03-26 MY MYPI20021077A patent/MY134081A/en unknown
- 2002-03-26 PE PE2002000240A patent/PE20021014A1/es not_active Application Discontinuation
- 2002-03-26 AR ARP020101114A patent/AR035795A1/es unknown
- 2002-03-27 TN TNTNSN02032A patent/TNSN02032A1/fr unknown
- 2002-03-27 PA PA20028542401A patent/PA8542401A1/es unknown
- 2002-03-28 AP APAP/P/2002/002467A patent/AP1689A/en active
2003
- 2003-07-17 IS IS6877A patent/IS6877A/is unknown
- 2003-08-13 MA MA27280A patent/MA26996A1/fr unknown
- 2003-08-25 BG BG108130A patent/BG108130A/bg unknown
- 2003-09-17 HR HR20030751A patent/HRP20030751A2/xx not_active Application Discontinuation
- 2003-09-26 NO NO20034299A patent/NO20034299L/no not_active Application Discontinuation
2004
- 2004-05-25 HK HK04103713A patent/HK1060724A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
DOP2002000364A (es)	2002-10-15
PE20021014A1 (es)	2002-11-12
NO20034299L (no)	2003-11-27
HK1060724A1 (en)	2004-08-20
HRP20030751A2 (en)	2005-08-31
JP4018545B2 (ja)	2007-12-05
CN1243723C (zh)	2006-03-01
HUP0303624A3 (en)	2005-06-28
CN1492852A (zh)	2004-04-28
NO20034299D0 (no)	2003-09-26
CZ20032534A3 (cs)	2004-07-14
TWI254038B (en)	2006-05-01
IL157009A0 (en)	2004-02-08
KR20030092032A (ko)	2003-12-03
BG108130A (bg)	2004-07-30
EA006154B1 (ru)	2005-10-27
SK11822003A3 (sk)	2004-09-08
AP1689A (en)	2006-12-07
PL365101A1 (en)	2004-12-27
WO2002079143A1 (en)	2002-10-10
EA200300777A1 (ru)	2003-12-25
HUP0303624A2 (hu)	2004-03-01
EP1373192A1 (en)	2004-01-02
BR0208455A (pt)	2004-03-02
JP2004531505A (ja)	2004-10-14
AP2002002467A0 (en)	2002-06-30
UY27227A1 (es)	2002-10-31
RS75303A (en)	2006-12-15
MA26996A1 (fr)	2004-12-20
IS6877A (is)	2003-07-17
CA2437113A1 (en)	2002-10-10
AR035795A1 (es)	2004-07-14
OA12553A (en)	2006-06-07
MY134081A (en)	2007-11-30
TNSN02032A1 (fr)	2005-12-23
GEP20063783B (en)	2006-04-10
NZ527012A (en)	2005-03-24
KR100564466B1 (ko)	2006-03-29
MXPA03006597A (es)	2004-10-15
EE200300469A (et)	2004-02-16

Publication	Publication Date	Title
PA8542401A1 (es)	2002-10-28	Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad
ECSP066336A (es)	2006-07-28	Derivados de 3-amino croman y 2-amino tetralin
AR056560A1 (es)	2007-10-10	Pirrolopiridinonas como moduladores cb1
UY29004A1 (es)	2006-02-24	Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
ECSP055640A (es)	2005-07-06	Composiciones de pirazol útiles como inhibidores de gsk-3
PA8596901A1 (es)	2004-11-26	Inhibidores de p38 y metodos de uso de ellos
PA8557401A1 (es)	2003-11-12	Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
AR036682A1 (es)	2004-09-29	Amidas heterociclicas, procedimiento para su preparacion, agentes que los contienen y su utilizacion
PE20080842A1 (es)	2008-08-11	Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
UY27872A1 (es)	2003-12-31	Inhibidores de caspasa y usos de los mismos.
AR072660A1 (es)	2010-09-15	Depuradores de sulfuro de hidrogeno y metodos para remover sulfuro de hidrogeno del asfalto
CR10062A (es)	2009-05-14	Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
HN2002000365A (es)	2003-07-23	Lactamas como antagonistas de taquiquininas
NI200500174A (es)	2006-04-17	Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias
PE20220425A1 (es)	2022-03-29	Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
CO5721005A2 (es)	2007-01-31	Triazolopirimidinas
AR076617A1 (es)	2011-06-22	Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.
CR11860A (es)	2011-02-25	Derivados de dibenzotiazepina y sus usos - 424
UY29204A1 (es)	2006-01-31	Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados
BR0213317A (pt)	2004-10-13	Uso de um composto, método de tratar um distúrbio relacionado com gastrina, composição farmacêutica, kit, usos de uma composição, e de um inibidor de bomba de próton, métodos de preparar uma composição farmacêutica e um composto, e, composto
AR044613A1 (es)	2005-09-21	Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4)
SV2003000931A (es)	2003-03-12	Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad ref.pcs10967
CO5611129A2 (es)	2006-02-28	Co-terapia con oxazolidinona
AR084019A1 (es)	2013-04-17	DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh
BRPI0409649A (pt)	2006-04-25	pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf